Thomas J. Schuetz - 02 Jan 2026 Form 4 Insider Report for Compass Therapeutics, Inc. (CMPX)

Reporting relationship: CEO, Director
Issuer ticker: CMPX
Reported as of: 02 Jan 2026
Net transaction value: +$1,292,500
SEC form: 4
Accepted by SEC: 05 Jan 2026, 16:33:41 UTC
Prior SEC filing: 18 Nov 2025
Next SEC filing: 12 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Thomas J. Schuetz

Key filing fact

Thomas J. Schuetz filed Form 4 for Compass Therapeutics, Inc. (CMPX) on 05 Jan 2026.

Key facts

This page summarizes Thomas J. Schuetz's Form 4 filing for Compass Therapeutics, Inc. (CMPX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 Jan 2026, 16:33.

Change

Previous filing in this sequence was filed on 18 Nov 2025.
Current net transaction value: +$1,292,500.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001591464 Primary reporting owner

Schuetz Thomas J.

Relationship: CEO, Director
Address: C/O COMPASS THERAPEUTICS, INC., 80 GUEST ST., SUITE 601, BOSTON
Signature: /s/ Thomas J. Schuetz
Signature date: 05 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CMPX transaction

Common Stock

Award

Transaction value: $1,292,500
Shares: +250,000
Change %: +3.9%
Price: $5.17
Shares after: 6,686,800
Date: 02 Jan 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CMPX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +2,000,000
Change %
Price: $0.000000
Shares after: 2,000,000
Date: 02 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,000,000
Exercise price: $5.17
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents restricted stock units ("RSU") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first vesting on January 2, 2027.

Footnote F2

250,000 of the shares represent unvested restricted stock units ("RSU") granted on February 8, 2023. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on February 8, 2024. 478,125 of the shares represent unvested restricted stock units ("RSU") granted on January 9, 2024. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 9, 2025. 250,000 of the shares represent unvested restricted stock units ("RSU") granted on January 2, 2026. Each RSU represents a contingent right to receive one share of common stock. The award is subject to service-based vesting conditions and vests in four equal annual installments, with the first installment vested on January 2, 2027.

Footnote F3

The options vest over 48 substantially equal monthly installments starting February 2, 2026.